TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today ...

In this video, I will talk about TransMedics (NASDAQ: TMDX) and the recent short-seller report. Watch the short video to learn more, consider subscribing, and click the special offer link below.

Philadelphia, Pennsylvania-- (Newsfile Corp. - January 10, 2025) - Kehoe Law Firm, P.C. is investigating potential securities class action claims on behalf of investors of TransMedics Group, Inc.

The report further alleges that TransMedics has been involved in kickbacks, billing fraud, unreported device failures, and ...

Short seller Scorpion Capital disclosed a short position in TransMedics Group Inc (NASDAQ:TMDX) accusing the organ transplant tech. company of fraudulent practices, including kickbacks, billing fraud, ...

TransMedics Group Inc (TMDX) stock saw a decline, ending the day at $72.55 which represents a decrease of $-6.12 or -7.78% from the prior close of $78.67. The stock opened at $75.81 and touched a low ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

TransMedics is a commercial-stage medical technology company working on organ transplant therapy. Check out more about the ...

In a report released today, Suraj Kalia from Oppenheimer maintained a Buy rating on TransMedics Group (TMDX – Research Report), with a price ...

Despite a Q3 revenue miss and temporary issues, TransMedics' long-term growth prospects remain strong, with plans for ...

Leading organ transplant technology provider TransMedics (NASDAQ: TMDX) increased sales by more than 100% in 10 straight ...